Stocks GlaxoSmithKline PLC

  • On the Pfizer earnings conference call this morning Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry."

  • Stocks advanced, boosted by a further drop in oil following the inventory report and expectations that the House would pass the Fannie Mae-Freddie Mac rescue plan.

  • gsk2.jpg

    GlaxoSmithKline's new chief executive set out plans to make the world's second largest drug maker a broader business with lower costs, but kept a cautious view on short-term prospects that knocked its shares.   

  • pharma_new2.jpg

    Roche Holdings' $43.7 billion bid to buy the rest of Genentech highlights drugmakers' growing reliance on biotech products.

  • genetech_logo_new.jpg

    Swiss drugmaker Roche Holding offered to acquire all outstanding shares in its U.S. partner Genentech for $43.7 billion in cash to reinforce its position in cancer medicines.

  • Lilly

    More than ten years after Pfizer brought Viagra to market and brought erectile dysfunction out of the closet a new survey says a lot of men are still too embarrassed to talk about impotence with their doctor.

  • merck_logo.jpg

    Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...

  • cadeuses2.jpg

    In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.

  • Cramer offers his plan of action to handle a 358-point decline.

  • graphic_word_ofthe_street.jpg

    The Dow closed sharply lower Friday, registering its third triple-digit loss in four sessions. What's the "Word on the Street?"

  • asco_new_logo.jpg

    This year, for the first time ever, ASCO agreed to let CNBC broadcast live from inside McCormick Place. It took years of reasoning, pleading, nagging and complaining to get inside. But finally, ASCO consented. In the past, the scientific organization has tried to keep more than an arm's distance from the financial media.

  • A bout of risk aversion dented European stocks on Tuesday as jitters grew over potential credit-related problems at banks and inflation, while typically defensive stocks such as pharmaceuticals and food rallied.

  • A study claims "the time has come" for researchers to study ED drugs as preventive medicine for the heart.

  • Amgen

    Up until last month, AMGN had been atop the list of pharmaceutical manufacturer donors and PFE was in a close second. But the CRP says they flip-flopped in the most recent month that figures are available. So far, in the 2008 election cycle, Pfizer's given $862,000 to candidates and Amgen has forked over $852,000.

  • Traders will be glued to the web Thursday night as thousands of cancer studies go online. What’s the trade as these studies potentially send shock waves through biotech stocks on Friday morning?

  • Palatin Technologies

    I like to think I have a nose for news. And, some might say, too much of a penchant for puns and alliteration. Impotence drug profits won't be going up big pharma's nose. The tiny New Jersey-based biotech company Palatin Technologies says it's giving up on its experimental nasal spray for erectile dysfunction.

  • Cramer makes the call on viewers' favorite stocks.

  • AMGEN

    The morning after Amgen reported its first quarter earnings my inbox runneth over with analyst research reports on the biotech behemoth. The company beat the Street by eight cents a share. But the focus remains on the anemia drug franchise.

  • Some late day earnings news could spill into Thursday's session: Apple shares rose after the company reported a 36 percent increase in profits to $1.05 billion. But the company guided third quarter below Wall Street estimates...

  • GlaxoSmithKline is paying big in an effort to find cures for diseases of aging. They are buying Sirtris Pharmaceuticals for $720M in cash, or $22.50/share. This price represents an 84% premium over SIRT's closing price yesterday. Two things are going on here...